# SCIENTIFIC PANEL ON CONTAMINANTS IN THE FOOD CHAIN

The 1<sup>st</sup> WG meeting on genotoxicity of beauvericin



15 April 2024 13:00-17:00 MINUTES - Agreed on 23 April 2024

Location: Webconference

#### Attendees:

o Working Group Members:

Margherita Bignami (chair), Emanuela Corsini, Ludovic Le Hégarat, Kevin Chipman

O Hearing Experts<sup>1</sup>:

Federico Cruciani

European Commission and/or Member States representatives:

Frans Verstraete

o EFSA:

Hans Steinkellner, Frederique Istace

Others:Not Applicable

#### I. Welcome and apologies for absence

The Chair welcomed the participants. No apologies were received. The participants introduced themselves.

### II. Adoption of agenda

The agenda was adopted without changes.

# III. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence<sup>2</sup> and the Decision of the Executive Director on Competing Interest Management<sup>3</sup>, EFSA screened the Annual Declarations of Interest filled out by the Working Group members invited to the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process, and no interests were declared orally by the members at the beginning of this meeting.

# IV. Agreement of previous meeting minutes

Not applicable.

# V. Scientific topic(s) for discussion

<sup>&</sup>lt;sup>1</sup> As defined in Article 34 of the Decision of the Executive Director concerning the selection of members of the Scientific Committee, the Scientific Panels, and the selection of external experts to assist EFSA with its scientific work: http://www.efsa.europa.eu/en/keydocs/docs/expertselection.pdf

#### MEETING MINUTES



Scientific opinion on the genotoxicity of beauvericin (Evaluation of the risks for health related to the presence of methylated arsenic species in food (EFSA-Q-2024-00184) $^{2}$ 

The WG members discussed the terms of reference for this opinion with the representative from the EC. Then the literature available and potentially relevant for the mandate was discussed. After that the draft structure and content of the opinion was discussed and tasks were allocated to the WG members.

### VI. Any Other Business

None

#### VII. Next meeting

2<sup>nd</sup> WG meeting: 16 May 13.00 - 17.00

<sup>&</sup>lt;sup>2</sup> https://open.efsa.europa.eu/questions/EFSA-Q-2024-00184?search=beauvericin